Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 4 institutions in 2 countries.
Verena K KöhlerComparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Veterinärplatz 1, 1210 Vienna, Austria.ORCID 0000-0001-5581-398X
Silvia CrescioliSt. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, 9th Floor, Tower Wing, Guy's Hospital, London SE1 9RT, UK.ORCID 0000-0002-1909-5957
Judit Fazekas-SingerComparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Veterinärplatz 1, 1210 Vienna, Austria.
Heather J BaxSt. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, 9th Floor, Tower Wing, Guy's Hospital, London SE1 9RT, UK.ORCID 0000-0003-0432-4160
Gerhard HoferInstitute of Molecular Biosciences, BioTechMed Graz, University of Graz, Humboldtstraße 50, 8010 Graz, Austria.
Christina L PrangerComparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Veterinärplatz 1, 1210 Vienna, Austria.
Karin HufnaglComparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Veterinärplatz 1, 1210 Vienna, Austria.
Rodolfo BianchiniComparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Veterinärplatz 1, 1210 Vienna, Austria.ORCID 0000-0003-0351-6937
Sabine FlickerInstitute of Pathophysiology and Allergy Research, Centre of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.ORCID 0000-0003-4768-8693
Walter KellerInstitute of Molecular Biosciences, BioTechMed Graz, University of Graz, Humboldtstraße 50, 8010 Graz, Austria.ORCID 0000-0002-2261-958X
Sophia N KaragiannisSt. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, 9th Floor, Tower Wing, Guy's Hospital, London SE1 9RT, UK.ORCID 0000-0002-4100-7810
Erika Jensen-JarolimComparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Veterinärplatz 1, 1210 Vienna, Austria.ORCID 0000-0003-4019-5765
University of Veterinary Medicine Vienna · ATGuy's Hospital · GBUniversity of Graz · ATMedical University of Vienna · AT
Funding
Austrian Science Fund MCCA W1248-B30Austrian Science Fund SFB-F4604Austrian Science Fund SFB F4606-B28Austrian Science Fund SFB-F4607Breast Cancer Now 147Cancer Research UK C30122/A11527Cancer Research UK C30122/A15774Cancer Research UK King's Health Partners Centre at King's College London naCRUK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre C10355/A15587European Federation of Immunological Societies short-term research fellowshipKarl-Franzens-Universität Graz Förderung Wissenschaftlicher NachwuchsMedical Research Council MR/L023091/1NIHR Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London IS-BRC-1215-20006The Guy's and St Thomas's Foundation Trust Charity Melanoma Special Fund na
6 · The paper itself
Abstract
Birch pollen allergy is among the most prevalent pollen allergies in Northern and Central Europe. This IgE-mediated disease can be treated with allergen immunotherapy (AIT), which typically gives rise to IgG antibodies inducing tolerance. Although the main mechanisms of allergen immunotherapy (AIT) are known, questions regarding possible Fc-mediated effects of IgG antibodies remain unanswered. This can mainly be attributed to the unavailability of appropriate tools, i.e., well-characterised recombinant antibodies (rAbs). We hereby aimed at providing human rAbs of several classes for mechanistic studies and as possible candidates for passive immunotherapy. We engineered IgE, IgG
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG · full record | OpenQuestion